Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study

Thoracic Cancer

Volumn 4, Issue 2, 2013, Pages 109-116

  Yu, Shufei ^a   Wang, Yan ^a   Li, Junling ^a   Hao, Xuezhi ^a   Wang, Bin ^a   Wang, Ziping ^a   Zhang, Xiangru ^a   Shi, Yuankai ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non small cell lung cancer

Indexed keywords

ERLOTINIB; GEFITINIB;

ADULT; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG ERUPTION; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY;

EID: 84876797287     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2012.00152.x     Document Type: Article

References (43)

1. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-34.
2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-59.
3. Comis RL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005; 10: 467-70.
4. Fukuoka M, Yano S, Giaccone G etal. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-46.
5. Kris MG, Natale RB, Herbst RS etal. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
6. Kim ES, Hirsh V, Mok T etal. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-18.
7. Thatcher N, Chang A, Parikh P etal. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37.
8. Chang GC, Tsai CM, Chen KC etal. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol 2006; 1: 520-5.
9. Mok TS, Wu YL, Thongprasert S etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
10. Chang JW, Chou CL, Huang SF etal. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 2007; 58: 414-7.
11. Gridelli C, Maione P, Galetta D etal. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2: 758-61.
12. Costa DB, Nguyen KS, Cho BC etal. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14: 7060-7.
13. Cho BC, Im CK, Park MS etal. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25: 2528-33.
14. Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008; 19: 2039-42.
15. Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 50: 417-8.
16. Sim SH, Han SW, Oh DY etal. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer 2009; 65: 204-7.
17. Garfield DH. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small cell lung carcinoma. J Clin Oncol 2005; 23: 7738-40.
18. Vasile E, Tibaldi C, Chella A, Falcone A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to Gefitinib. J Thorac Oncol 2008; 3: 912-4.
19. Wong AS, Soong R, Seah SB etal. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008; 3: 400-4.
20. Zhou ZT, Xu XH, Wei Q, Lu MQ, Wang J, Wen CH. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol 2009; 64: 1123-7.
21. Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 65: 1023-8.
22. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
23. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009; 63: 315-21.
24. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-9.
25. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 2011; 37: 456-64.
26. Yang C, Shih J, Su W etal. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2). Ann Oncol 2010; 21 (Suppl. 8): viii 123.
27. Takahashi T, Boku N, Murakami H etal. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012 Jan 17. [Epub ahead of print].
28. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012 Jan 16. [Epub ahead of print].
29. Bang Y, Kwak EL, Shaw AT etal. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28 (Suppl. 18): 3.
30. Ross HJ, Blumenschein GR Jr, Aisner J etal. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010; 16: 1938-49.
31. Lee JS, Hirsh V, Park K etal. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114-21.
32. Sequist LV, von Pawel J, Garmey EG etal. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-15.
33. Goto Y, Sekine I, Tanioka M etal. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 2011 July 13. [Epub ahead of print].
34. Zito CR, Jilaveanu LB, Anagnostou V etal. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS ONE 2012; 7 (2): e31331.
35. Proia DA, Sang J, He S etal. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs 2012 Jan10. [Epub ahead of print].
36. Chang A, Parikh P, Thongprasert S etal. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1: 847-55.
37. Shepherd FA, Rodrigues Pereira J, Ciuleanu T etal. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-32.
38. Kim ST, Lee J, Kim JH etal. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 2010; 116: 3025-33.
39. Asami K, Kawahara M, Atagi S, Kawaguchi T, Okishio K. Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 2011 73: 211-6.
40. McKillop D, Partridge EA, Kemp JV etal. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005; 4: 641-9.
41. Fukuoka M, Wu YL, Thongprasert S etal. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
42. Zhu CQ, Santos G, Ding K etal. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-75.
43. Heon S, Yeap BY, Lindeman NI, Rabin MS, Jackman DM, Johnson BE. Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy. J Clin Oncol 2011; 29 ( Suppl.): Abstract 7607.